Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 1
2009 2
2010 3
2011 6
2012 1
2013 3
2014 2
2015 1
2016 2
2017 2
2018 4
2019 1
2020 1
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Results by year
Filters applied: . Clear all
Page 1
Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C. Orlando D, et al. Among authors: hagedoorn rs. Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3. Cancer Res. 2018. PMID: 29615432 Free article.
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: hagedoorn rs. J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14. J Clin Invest. 2019. PMID: 30640174 Free PMC article.
Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, Heemskerk MHM. Bijen HM, et al. Among authors: hagedoorn rs. Mol Ther. 2018 May 2;26(5):1206-1214. doi: 10.1016/j.ymthe.2018.02.017. Epub 2018 Feb 23. Mol Ther. 2018. PMID: 29567312 Free PMC article.
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
van der Lee DI, Koutsoumpli G, Reijmers RM, Honders MW, de Jong RCM, Remst DFG, Wachsmann TLA, Hagedoorn RS, Franken KLMC, Kester MGD, Harber KJ, Roelofsen LM, Schouten AM, Mulder A, Drijfhout JW, Veelken H, van Veelen PA, Heemskerk MHM, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: hagedoorn rs. Cancers (Basel). 2021 Oct 27;13(21):5390. doi: 10.3390/cancers13215390. Cancers (Basel). 2021. PMID: 34771556 Free PMC article.
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19.
Roukens AHE, Pothast CR, König M, Huisman W, Dalebout T, Tak T, Azimi S, Kruize Y, Hagedoorn RS, Zlei M, Staal FJT, de Bie FJ, van Dongen JJM, Arbous SM, Zhang JLH, Verheij M, Prins C, van der Does AM, Hiemstra PS, de Vries JJC, Janse JJ, Roestenberg M, Myeni SK, Kikkert M, Yazdanbakhsh M, Heemskerk MHM, Smits HH, Jochems SP; in collaboration with BEAT-COVID group; in collaboration with COVID-19 LUMC group. Roukens AHE, et al. Among authors: hagedoorn rs. Nat Immunol. 2022 Jan;23(1):23-32. doi: 10.1038/s41590-021-01095-w. Epub 2021 Dec 22. Nat Immunol. 2022. PMID: 34937933
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ. Gezgin G, et al. Among authors: hagedoorn rs. JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729. JAMA Ophthalmol. 2017. PMID: 28448663 Free PMC article.
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, Hoogstaten C, Veld SAJ, Hageman L, van Liempt PAG, Zwaginga JJ, Meij P, Veelken H, Falkenburg JHF, Heemskerk MHM. van Balen P, et al. Among authors: hagedoorn rs. Front Immunol. 2020 Aug 20;11:1804. doi: 10.3389/fimmu.2020.01804. eCollection 2020. Front Immunol. 2020. PMID: 32973756 Free PMC article. Clinical Trial.
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH. Jahn L, et al. Among authors: hagedoorn rs. Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4. Blood. 2017. PMID: 28053195 Free article.
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: hagedoorn rs. Mol Ther. 2021 Aug 8:S1525-0016(21)00404-4. doi: 10.1016/j.ymthe.2021.08.010. Online ahead of print. Mol Ther. 2021. PMID: 34371177
31 results